Relief from within: A peptide therapy for fibrosis

Science Translational Medicine

Volumn 4, Issue 136, 2012, Pages

  Atamas, Sergei P ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; BLEOMYCIN; COLLAGEN 18; COLLAGEN TYPE 1; E4 PEPTIDE; EARLY GROWTH RESPONSE FACTOR 1; ENDOSTATIN; FIBRONECTIN; GAMMA INTERFERON; PLACEBO; PROTEIN LYSINE 6 OXIDASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AUTOIMMUNITY; BLOOD CLOTTING DISORDER; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLLAGEN SYNTHESIS; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; INFLAMMATORY CELL; LUNG FIBROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SCLERODERMA; SHORT SURVEY; SKIN FIBROSIS; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; ANIMAL; ARTICLE; CHEMISTRY; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOSTATINS; FIBROSIS; HUMANS; PEPTIDES;

EID: 84861731402     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004138     Document Type: Short Survey

References (10)

1. V. D. Steen, T. A. Medsger, Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66, 940-944 (2007).
2. B. Ley, H. R. Collard, T. E. King Jr., Clinical course and prediction of survival in idiopathic pulmonary fi brosis. Am. J. Respir. Crit. Care Med. 183, 431-440 (2011).
3. R. M. du Bois, Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug Discov. 9, 129-140 (2010).
4. Y. Yamaguchi, T. Takihara, R. A. Chambers, K. L. Veraldi, A. T. Larregina, C. A. Feghali-Bostwick, A peptide derived from endostatin ameliorates organ fi brosis. Sci. Transl. Med. 4, 136ra71 (2012).
5. T. E. King Jr., C. Albera, W. Z. Bradford, U. Costabel, P. Hormel, L. Lancaster, P. W. Noble, S. A. Sahn, J. Szwarcberg, M. Thomeer, D. Valeyre, R. M. du Bois; INSPIRE Study Group, Eff ect of interferon gamma-1b on survival in patients with idiopathic pulmonary fi brosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet 374, 222-228 (2009).
6. G. Raghu, K. K. Brown, W. Z. Bradford, K. Starko, P. W. Noble, D. A. Schwartz, T. E. King Jr.; Idiopathic Pulmonary Fibrosis Study Group, A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fi brosis. N. Engl. J. Med. 350, 125-133 (2004).
7. I. G. Luzina, N. W. Todd, A. T. Iacono, S. P. Atamas, Roles of T lymphocytes in pulmonary fi brosis. J. Leukoc. Biol. 83, 237-244 (2008).
8. S. P. Atamas, B. White, Cytokine regulation of pulmonary fi brosis in scleroderma. Cytokine Growth Factor Rev. 14, 537-550 (2003).
9. A. G. Marneros, B. R. Olsen, Physiological role of collagen XVIII and endostatin. FASEB J. 19, 716-728 (2005).
10. S. Bhattacharyya, M. Wu, F. Fang, W. Tourtellotte, C. Feghali-Bostwick, J. Varga, Early growth response transcription factors: Key mediators of fi brosis and novel targets for anti-fi brotic therapy. Matrix Biol. 30, 235-242 (2011).